Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

This study found that NKIRAS2 expression affects skin tumor suppression and HRAS-driven transformation in mice, indicating its role in carcinogenesis depends on expression level and cellular context.

This study reports a case of complete hair regrowth in lichen planopilaris after 12 weeks of treatment with ixekizumab, suggesting its potential as a targeted therapy.

This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.

This study found that EGFR and MEK inhibitors may induce acneiform skin toxicities by interacting with the skin bacterium Cutibacterium acnes to increase IL-36γ and IL-8 production in keratinocytes.

This review discusses evidence from recent clinical trials showing inclisiran effectively lowers LDL cholesterol levels in patients with cardiovascular disease, leading to its use in the UK despite not being approved by the FDA.

This study reports that a patient with rare linear lichen planopilaris experienced complete hair regrowth after 12 weeks of treatment with the antibody ixekizumab, suggesting it as a potential targeted therapy.

This source discusses that while oral JAK inhibitors are used for treating lichen planopilaris and frontal fibrosing alopecia, they carry significant risk of adverse events; two cases showed promising results using tofacitinib cream as a safer topical alternative.

In this study, researchers found that miR-3606-3p is significantly downregulated in skin fibrosis and correlates with disease severity, with its ability to inhibit key signaling pathways suggesting potential therapeutic applications for conditions like systemic sclerosis and keloids.

Keratin 79 cells help form and regenerate hair canals.

In this study, baricitinib treatment improved the differentiation of skin-derived precursors into adipocytes for diseases like Hutchinson-Gilford progeria syndrome, suggesting potential benefits when combined with lonafarnib.

This study reports that flaky skin mice exhibit skin and nail features that closely resemble human psoriasis vulgaris, suggesting they may serve as a natural model for this condition.

This study found that bursts of ERK activation in the epidermis of mice were linked to cell division, supporting synchronized cell proliferation and transient ERK activity in living tissues.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

Using molecular dynamics simulations, this study explored the uptake processes of JAK inhibitors on stratum corneum and hair follicle membranes, revealing a unique interaction mechanism in the hair follicle and offering insights into transdermal drug delivery pathways.

This article reviews the JAK signaling pathway and the development of ruxolitinib cream as a targeted treatment for inflammatory skin diseases, reporting no new clinical results.

Junctional proteins stabilize the inner root sheath and connect the companion layer in human hair.

This study observed that keratosis pilaris is the most prevalent follicular keratotic disease, especially in adolescent and young adult females, and emphasized the key role of dermoscopy and histopathology in distinguishing it from other similar disorders and aiding in diagnosis.

This source highlights that intraocular foreign bodies are urgent ophthalmologic emergencies requiring prompt diagnosis and treatment to prevent blindness and eye loss, with most cases involving the posterior segment of the eye.

In this case report, a female patient with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvement in symptoms, including hair loss and lesions, after six months of treatment with tofacitinib, with no recurrence or adverse effects over a two-year follow-up.

In this study, treatment with human follicular keratinocyte-conditioned media improved the trichogenicity of cultured dermal cells by activating key signalling pathways, suggesting its potential use in cell therapy for hair loss.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

This study describes a method to create keratin hydrogels with adjustable erosion rates by mixing different ratios of keratose and kerateine, enabling controlled release of therapeutic agents like insulin-like growth factor 1.

This study suggests that interfollicular epidermal keratinocytes with stem-like features may serve as an alternative to follicular keratinocytes for hair regeneration by supporting hair follicle morphogenesis in vivo.

This study found that Krox20 marks a diverse stem cell population in mouse hair follicles, which significantly contributes to the interfollicular epidermis and regulates epidermal homeostasis.

This study found that mouse FLRG protein, a secreted glycoprotein, is expressed in certain tissues and plays a role distinct from follistatin during wound healing, suggesting different functions in vivo.

KLHL24-mutant stem cells help understand skin and heart disease.

This study observed that keratose hydrogels sustained ciprofloxacin release over three weeks and inhibited Staphylococcus aureus growth in vitro for 23 days and in mice for 2 weeks.

This study found that Ishige sinicola ethanol extract and its butanol fraction can protect against lipopolysaccharide-induced muscle atrophy in C2C12 myotubes through antioxidant and anti-inflammatory activities.